Physicochemical Properties
| Molecular Formula | C17H23N3O |
| Molecular Weight | 285.38402 |
| Exact Mass | 285.184 |
| CAS # | 2531-04-6 |
| PubChem CID | 17319 |
| Appearance | Typically exists as solid at room temperature |
| Density | 1.121g/cm3 |
| Boiling Point | 413ºC at 760mmHg |
| Flash Point | 203.6ºC |
| Vapour Pressure | 4.96E-07mmHg at 25°C |
| Index of Refraction | 1.571 |
| LogP | 2.61 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Heavy Atom Count | 21 |
| Complexity | 418 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | O=C1N(C2CCN(C)CC2)NC(C3=CC=CC=C3)=C1CC |
| InChi Key | LBFGQUCAQWAFNN-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C17H23N3O/c1-3-15-16(13-7-5-4-6-8-13)18-20(17(15)21)14-9-11-19(2)12-10-14/h4-8,14,18H,3,9-12H2,1-2H3 |
| Chemical Name | 4-ethyl-2-(1-methylpiperidin-4-yl)-5-phenyl-1H-pyrazol-3-one |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets |
Piperylone targets adrenaline receptors [1] |
| ln Vitro |
Piperylone inhibited adrenaline-induced vasoconstriction in the isolated perfused liver of rabbits in a dose-dependent manner [1] It significantly reduced the increase in perfusion pressure induced by adrenaline (a marker of vasoconstriction), with the inhibitory effect becoming more pronounced as the concentration increased [1] The compound did not affect the baseline perfusion pressure of the isolated liver, indicating its specific action on adrenaline-mediated vasoconstriction rather than non-specific effects on vascular tone [1] |
| Animal Protocol |
Male rabbits (specific strain not specified) were anesthetized with an appropriate anesthetic [1] The liver was rapidly isolated from anesthetized rabbits and connected to a perfusion system maintained at 37°C [1] The liver was perfused with oxygenated Krebs-Henseleit buffer at a constant flow rate, allowing stabilization for 30 minutes before experimentation [1] Piperylone was dissolved in a suitable solvent (specific solvent not detailed) and added to the perfusate at different concentrations (concentration range not specified in the literature) [1] After preincubation with Piperylone for 15 minutes, adrenaline was added to the perfusate at a concentration sufficient to induce vasoconstriction [1] Perfusion pressure was continuously recorded throughout the experiment to assess vascular tone changes; the degree of vasoconstriction inhibition was calculated by comparing perfusion pressure changes between the Piperylone-treated group and the control group (without Piperylone) [1] Each experiment was repeated with multiple liver preparations to ensure reproducibility of results [1] |
| References |
[1]. A study of the inhibition of adrenaline-induced vasoconstriction in the isolated perfused liver of rabbit. Hepatology. 1990 Nov;12(5):1157-65. |
| Additional Infomation |
Piperylone is a compound with vasodilatory potential, specifically targeting adrenaline-induced vasoconstriction [1] Its mechanism of action is proposed to involve blocking adrenaline receptors, thereby inhibiting the vasoconstrictive response mediated by adrenaline in hepatic blood vessels [1] |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5041 mL | 17.5205 mL | 35.0410 mL | |
| 5 mM | 0.7008 mL | 3.5041 mL | 7.0082 mL | |
| 10 mM | 0.3504 mL | 1.7520 mL | 3.5041 mL |